Last reviewed · How we verify
Imipenem/Cilastatin/Relebactam
Imipenem/Cilastatin/Relebactam is a Carbapenem antibiotic with beta-lactamase inhibitor Small molecule drug developed by Evopoint Biosciences Inc.. It is currently FDA-approved for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Also known as: Recarbrio, RECARBRIO™.
Imipenem/cilastatin/relebactam is a combination of a broad-spectrum beta-lactam antibiotic, a renal dehydropeptidase inhibitor, and a beta-lactamase inhibitor that together kill bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.
Imipenem/cilastatin/relebactam is a combination of a broad-spectrum beta-lactam antibiotic, a renal dehydropeptidase inhibitor, and a beta-lactamase inhibitor that together kill bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation. Used for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
At a glance
| Generic name | Imipenem/Cilastatin/Relebactam |
|---|---|
| Also known as | Recarbrio, RECARBRIO™ |
| Sponsor | Evopoint Biosciences Inc. |
| Drug class | Carbapenem antibiotic with beta-lactamase inhibitor |
| Target | Bacterial penicillin-binding proteins; serine beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Imipenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Cilastatin prevents renal metabolism of imipenem, increasing its bioavailability. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by serine beta-lactamases, extending activity against resistant gram-negative bacteria including carbapenem-resistant Enterobacteriaceae (CRE).
Approved indications
- Complicated urinary tract infections (cUTI) including pyelonephritis
- Complicated intra-abdominal infections (cIAI)
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
Common side effects
- Nausea
- Diarrhea
- Headache
- Phlebitis at infusion site
- Seizures (rare, especially with renal impairment)
Key clinical trials
- Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021) (PHASE2, PHASE3)
- Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) (PHASE3)
- Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016) (PHASE3)
- Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis (PHASE4)
- Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients (PHASE4)
- PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN (PHASE2)
- Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections (PHASE4)
- Imipenem/Cilastatin/Relebactam PK in ECMO (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imipenem/Cilastatin/Relebactam CI brief — competitive landscape report
- Imipenem/Cilastatin/Relebactam updates RSS · CI watch RSS
- Evopoint Biosciences Inc. portfolio CI
Frequently asked questions about Imipenem/Cilastatin/Relebactam
What is Imipenem/Cilastatin/Relebactam?
How does Imipenem/Cilastatin/Relebactam work?
What is Imipenem/Cilastatin/Relebactam used for?
Who makes Imipenem/Cilastatin/Relebactam?
Is Imipenem/Cilastatin/Relebactam also known as anything else?
What drug class is Imipenem/Cilastatin/Relebactam in?
What development phase is Imipenem/Cilastatin/Relebactam in?
What are the side effects of Imipenem/Cilastatin/Relebactam?
What does Imipenem/Cilastatin/Relebactam target?
Related
- Drug class: All Carbapenem antibiotic with beta-lactamase inhibitor drugs
- Target: All drugs targeting Bacterial penicillin-binding proteins; serine beta-lactamases
- Manufacturer: Evopoint Biosciences Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Complicated urinary tract infections (cUTI) including pyelonephritis
- Indication: Drugs for Complicated intra-abdominal infections (cIAI)
- Indication: Drugs for Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Also known as: Recarbrio, RECARBRIO™